ZAMBELLI, LUCA
ZAMBELLI, LUCA
Universita' degli Studi di MILANO
Anticancer Drugs-Related Hypogonadism in Male Patients with Advanced Cancers on Active Treatment: A Systematic Review
2024 G. Massa, L. Zambelli, E. Zecca, M. Shkodra, G. Tinè, A. Caraceni
Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications
2022 F. Ligorio, L. Zambelli, G. Fucà, R. Lobefaro, M. Santamaria, E. Zattarin, F. de Braud, C. Vernieri
The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab
2021 F. Ligorio, G. Fuca, E. Zattarin, R. Lobefaro, L. Zambelli, R. Leporati, C. Rea, G. Mariani, G.V. Bianchi, G. Capri, F. de Braud, C. Vernieri
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients
2021 F. Ligorio, L. Zambelli, A. Bottiglieri, L. Castagnoli, E. Zattarin, R. Lobefaro, A. Ottini, A. Vingiani, S.M. Pupa, G.V. Bianchi, G. Capri, G. Pruneri, F. de Braud, C. Vernieri
Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)epositive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy
2020 F. Ligorio, L. Zambelli, A. Bottiglieri, L. Castagnoli, E. Zattarin, R. Loberfaro, A. Belfiore, A. Vingiani, G. Pruneri, G. Bianchi, G. Capri, S. Pupa, F. de Braud, C. Vernieri